European Lithium Limited · ISIN: AU000000EUR7 · Research | Analyses | Ratings

Buy

Original-Research: European Lithium Limited - from First Berlin Equity Research GmbH 20.12.2024 / 16:41 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude certain stock exchange transactions. Classification of First Berlin Equity Research GmbH to European Lithium Limited Company Name: European...

ASX:EUR Price indication powered by TradingView

About the publication

+++ Corporate Insights +++- Company news, directors dealings, net short positions

Just become a member of the community.

Current analyst assessments

On this page you will find current analyst assessments of renowned research houses, which make their assessments on the business development of listed companies available for publication and distribution via our content partner EQS-Newswire.
Ratings
Buy
Sell
Reduce
Hold
New admission
Suspended
All Sources
Hardman & Co.
Edison
BankM
East Value
First Berlin
GBC
Montega
NuWays
Parmantier & Cie.
Sphene Capital
New mwb Research
Reset Filter
This might be interesting for you as well
Equity Story (22)
Directors Dealings (0)
Short Selling (DE) (0)
Short Selling (UK) (0)
Source: First Berlin Equity Research GmbH
22 November 2024 11:06AM
BUY
CA14161Y2006
Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH 22.11.2024 / 11:05 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to...
Cardiol Therapeutics Inc
About the publication
Source: First Berlin Equity Research GmbH
28 October 2024 03:46PM
Buy
CA14161Y2006
Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH 28.10.2024 / 15:45 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to...
Cardiol Therapeutics Inc
About the publication
Source: First Berlin Equity Research GmbH
14 June 2024 02:52PM
Buy
CA14161Y2006
Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH Classification of First Berlin Equity Research GmbH to Cardiol Therapeutics Inc Company Name: Cardiol Therapeutics Inc ISIN: CA14161Y2006 Reason for the research: Update Recommendation: Buy from: 14.06.2024 Target price: USD8.50 Target price on sight of: 12 months...
Cardiol Therapeutics Inc
About the publication
Source: First Berlin Equity Research GmbH
27 February 2024 02:16PM
Buy
CA14161Y2006
Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH Classification of First Berlin Equity Research GmbH to Cardiol Therapeutics Inc Company Name: Cardiol Therapeutics Inc ISIN: CA14161Y2006 Reason for the research: Update Recommendation: Buy from: 27.02.2024 Target price: USD 3.60 Target price on sight of: 12 month...
Cardiol Therapeutics Inc
About the publication
Source: First Berlin Equity Research GmbH
19 January 2024 12:41PM
Buy
CA14161Y2006
Original-Research: Cardiol Therapeutics Inc - von First Berlin Equity Research GmbH Einstufung von First Berlin Equity Research GmbH zu Cardiol Therapeutics Inc Unternehmen: Cardiol Therapeutics Inc ISIN: CA14161Y2006 Anlass der Studie: Update Empfehlung: Buy seit: 19.01.2024 Kursziel: USD 3.60 Kursziel auf Sicht von: 12 months Letzte Ratingänderu...
Cardiol Therapeutics Inc
About the publication
Source: First Berlin Equity Research GmbH
30 August 2023 03:06PM
Buy
CA14161Y2006
Original-Research: Cardiol Therapeutics Inc - von First Berlin Equity Research GmbH Einstufung von First Berlin Equity Research GmbH zu Cardiol Therapeutics Inc Unternehmen: Cardiol Therapeutics Inc ISIN: CA14161Y2006 Anlass der Studie: Update Empfehlung: Buy seit: 30.08.2023 Kursziel: USD 3,60 / €3,30 Kursziel auf Sicht von: 12 months Letzte Rati...
Cardiol Therapeutics Inc
About the publication
Source: First Berlin Equity Research GmbH
24 May 2023 01:01PM
Buy
CA14161Y2006
Original-Research: Cardiol Therapeutics Inc - von First Berlin Equity Research GmbH Einstufung von First Berlin Equity Research GmbH zu Cardiol Therapeutics Inc Unternehmen: Cardiol Therapeutics Inc ISIN: CA14161Y2006 Anlass der Studie: Update Empfehlung: Buy seit: 24.05.2023 Kursziel: USD 3,60 (€3,30) Kursziel auf Sicht von: 12 Monate Letzte Ratin...
Cardiol Therapeutics Inc
About the publication
Source: First Berlin Equity Research GmbH
24 May 2023 01:01PM
Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy
CA14161Y2006
Original-Research: Cardiol Therapeutics Inc - von First Berlin Equity Research GmbH Einstufung von First Berlin Equity Research GmbH zu Cardiol Therapeutics Inc Unternehmen: Cardiol Therapeutics Inc ISIN: CA14161Y2006 Anlass der Studie: Update Empfehlung: Buy seit: 24.05.2023 Kursziel: USD 3,60 (€3,30) Kursziel auf Sicht von: 12 Monate Letzte Ratin...
Cardiol Therapeutics Inc
About the publication
Source: First Berlin Equity Research GmbH
11 April 2023 03:26PM
Buy
CA14161Y2006
Original-Research: Cardiol Therapeutics Inc - von First Berlin Equity Research GmbH Einstufung von First Berlin Equity Research GmbH zu Cardiol Therapeutics Inc Unternehmen: Cardiol Therapeutics Inc ISIN: CA14161Y2006 Anlass der Studie: Aufnahme der Coverage Empfehlung: Buy seit: 11.04.2023 Kursziel: USD 3,60 (€3,30) Kursziel auf Sicht von: 12 Mona...
Cardiol Therapeutics Inc
About the publication
Source: First Berlin Equity Research GmbH
11 April 2023 03:26PM
Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy
CA14161Y2006
Original-Research: Cardiol Therapeutics Inc - von First Berlin Equity Research GmbH Einstufung von First Berlin Equity Research GmbH zu Cardiol Therapeutics Inc Unternehmen: Cardiol Therapeutics Inc ISIN: CA14161Y2006 Anlass der Studie: Aufnahme der Coverage Empfehlung: Buy seit: 11.04.2023 Kursziel: USD 3,60 (€3,30) Kursziel auf Sicht von: 12 Mona...
Cardiol Therapeutics Inc
About the publication
Source: GBC AG
14 May 2022 09:01AM
Cardiol Therapeutics Inc. (von GBC AG): International Investment Forum
CA14161Y2006
Original-Research: Cardiol Therapeutics Inc. - von GBC AG Einstufung von GBC AG zu Cardiol Therapeutics Inc. Unternehmen: Cardiol Therapeutics Inc. ISIN: CA14161Y2006 Anlass der Studie: Empfehlung: International Investment Forum Letzte Ratingänderung: Analyst: Julien Desrosiers; Felix Haugg Upcoming Investor Event: Cardiol Therapeutics Inc. to pr...
Cardiol Therapeutics Inc.
About the publication
Source: GBC AG
10 February 2022 12:21PM
Cardiol Therapeutics Inc. (von GBC AG): 17.49 CAD
CA14161Y2006
Original-Research: Cardiol Therapeutics Inc. - von GBC AG Einstufung von GBC AG zu Cardiol Therapeutics Inc. Unternehmen: Cardiol Therapeutics Inc. ISIN: CA14161Y2006 Anlass der Studie: Company presentation Empfehlung: 17.49 CAD Kursziel: BUY Kursziel auf Sicht von: 31.12.2022 Letzte Ratingänderung: - Analyst: Julien Desrosiers; Felix Haugg Upcomin...
Cardiol Therapeutics Inc.
About the publication
Source: GBC AG
16 November 2021 11:01AM
Cardiol Therapeutics (von GBC AG): BUY
CA14161Y2006
Original-Research: Cardiol Therapeutics - von GBC AG Einstufung von GBC AG zu Cardiol Therapeutics Unternehmen: Cardiol Therapeutics ISIN: CA14161Y2006 Anlass der Studie: Research Update Empfehlung: BUY Kursziel: 17,49 CAD Kursziel auf Sicht von: 31.12.2022 Letzte Ratingänderung: Analyst: Julien Desrosiers; Felix Haugg GBC AG to present an investo...
Cardiol Therapeutics
About the publication
Source: GBC AG
11 October 2021 02:02PM
Cardiol Therapeutics (von GBC AG): BUY
CA14161Y2006
Original-Research: Cardiol Therapeutics - von GBC AG Einstufung von GBC AG zu Cardiol Therapeutics Unternehmen: Cardiol Therapeutics ISIN: CA14161Y2006 Anlass der Studie: Research Comment Empfehlung: BUY Kursziel: 17,49 CAD Kursziel auf Sicht von: 31.12.2022 Letzte Ratingänderung: Analyst: Julien Desrosiers; Felix Haugg Upcoming Investor Event: Ca...
Cardiol Therapeutics
About the publication
Source: GBC AG
13 September 2021 12:01PM
Cardiol Therapeutics Inc. (von GBC AG): Kaufen
CA14161Y2006
Original-Research: Cardiol Therapeutics Inc. - von GBC AG Einstufung von GBC AG zu Cardiol Therapeutics Inc. Unternehmen: Cardiol Therapeutics Inc. ISIN: CA14161Y2006 Anlass der Studie: Research Comment Empfehlung: Buy Kursziel: 17,49 CAD Letzte Ratingänderung: Analyst: Julien Desrosiers; Felix Haugg Die FDA hat die Freigabe zur Durchführung de...
Cardiol Therapeutics Inc.
About the publication
Source: GBC AG
09 September 2021 02:01PM
Cardiol Therapeutics (von GBC AG): BUY
CA14161Y2006
Original-Research: Cardiol Therapeutics - von GBC AG Einstufung von GBC AG zu Cardiol Therapeutics Unternehmen: Cardiol Therapeutics ISIN: CA14161Y2006 Anlass der Studie: Research Comment Empfehlung: BUY Kursziel: 17,49 CAD Kursziel auf Sicht von: 31.12.2022 Letzte Ratingänderung: Analyst: Julien Desrosiers; Felix Haugg On August 24th, Cardiol The...
Cardiol Therapeutics
About the publication
Source: GBC AG
13 August 2021 11:31AM
Cardiol Therapeutics (von GBC AG): Buy
CA14161Y2006
Original-Research: Cardiol Therapeutics - von GBC AG Einstufung von GBC AG zu Cardiol Therapeutics Unternehmen: Cardiol Therapeutics ISIN: CA14161Y2006 Anlass der Studie: Research Comment Empfehlung: Buy Kursziel: 17.49 CAD Kursziel auf Sicht von: 31.12.2022 Letzte Ratingänderung: Analyst: Julien Desrosiers; Felix Haugg Cardiol Therapeutics succes...
Cardiol Therapeutics
About the publication
Source: GBC AG
23 June 2021 03:03PM
Cardiol Therapeutics (von GBC AG): BUY
CA14161Y2006
Original-Research: Cardiol Therapeutics - von GBC AG Einstufung von GBC AG zu Cardiol Therapeutics Unternehmen: Cardiol Therapeutics ISIN: CA14161Y2006 Anlass der Studie: Initial Coverage Report Empfehlung: BUY seit: 23.06.2021 Kursziel: 15,77 CAD Kursziel auf Sicht von: 31.12.2021 Letzte Ratingänderung: - Analyst: Julien Desrosiers; Felix Haugg On...
Cardiol Therapeutics
About the publication
Source: GBC AG
22 April 2021 02:02PM
Cardiol Therapeutics (von GBC AG):
CA14161Y2006
Original-Research: Cardiol Therapeutics - von GBC AG Einstufung von GBC AG zu Cardiol Therapeutics Unternehmen: Cardiol Therapeutics ISIN: CA14161Y2006 Anlass der Studie: Management Interview Letzte Ratingänderung: Analyst: Julien Desrosiers; Felix Haugg The Company announced topline results from its Phase I Single and Multiple Ascending Dose Clin...
Cardiol Therapeutics
About the publication
Source: GBC AG
29 March 2021 03:16PM
Cardiol Therapeutics (von GBC AG):
CA14161Y2006
Original-Research: Cardiol Therapeutics - von GBC AG Einstufung von GBC AG zu Cardiol Therapeutics Unternehmen: Cardiol Therapeutics ISIN: CA14161Y2006 Anlass der Studie: Research Comment Letzte Ratingänderung: - Analyst: Julien Desrosiers; Felix Haugg GBC Research Watchlist: Cardiol Therapeutics Inc. 'The right moment to participate in this exci...
Cardiol Therapeutics
About the publication
More Cardiol Therapeutics Inc related information
Type Total Last Made by Go to
Equity Story 22 22nd November 2024 EQS Group AG EQS
Directors Dealings 0 - - DD
Short Seller (DE) 0 - - SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Info
The information presented here was provided by our content partner EQS. The assessments of the analyst houses were transmitted in the original via the news service EQS-Newswire for publication via the affiliated distribution networks.
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.